News

Gain Therapeutics Heads to H.C. Wainwright Investment Conference

Gain Therapeutics Heads to H.C. Wainwright Investment Conference

Gain Therapeutics to Participate in Investment Conference

BETHESDA, Md. — Gain Therapeutics, Inc. (Nasdaq: GANX) is preparing to make a significant impression at the H.C. Wainwright 26th Annual Global Investment Conference, which will be held from September 9 to September 11, 2024. Key representatives from Gain, including Gene Mack, the Interim CEO and current CFO, along with Dr. Jonas Hannestad, the Chief Medical Officer, will be engaging in discussions and one-on-one meetings throughout the event.

Engaging with the Gain Therapeutics Team

For those interested in exploring potential collaborations or learning more about Gain Therapeutics, reaching out via email is encouraged. This conference presents a wonderful opportunity for attendees to connect directly with industry leaders, gain insights into Gain's innovative strategies, and discuss future advancements in biotechnology.

Gain Therapeutics: Innovations in Biotechnology

Gain Therapeutics, Inc. is at the forefront of biotechnology advancements, particularly in the development of allosteric therapies. Their lead candidate, GT-02287, is currently undergoing a Phase 1 clinical trial aimed at treating Parkinson’s disease, marking significant progress toward potentially transformative treatments.

Magellan™ Drug Discovery Platform

Leveraging state-of-the-art technology, Gain’s Magellan™ drug discovery platform utilizes AI-supported structural biology, proprietary algorithms, and supercomputer-powered models. This platform excels at identifying new allosteric binding sites on proteins linked to various diseases, setting Gain Therapeutics apart in the drug development arena.

Tackling Complex Health Challenges

The biotechnology sector is constantly evolving, and Gain Therapeutics is leading the charge with discoveries that could significantly reshape therapeutic landscapes. By concentrating on difficult-to-treat conditions, including neurodegenerative diseases and rare genetic disorders, Gain is dedicated to developing innovative treatments that could benefit numerous patients.

Distinctive Approach to Drug Discovery

Gain's approach incorporates machine learning tools and a comprehensive virtual compound library, enabling their team to discover and validate various small molecule hits. This innovative methodology gives Gain a competitive advantage, allowing the company to explore extensive chemical spaces and enhance their research initiatives.

Investor and Media Contacts

For additional inquiries or to connect with Gain Therapeutics, please reach out to investor contacts Apaar Jammu and Chuck Padala via their respective emails: ajammu@gaintherapeutics.com and chuck@lifesciadvisors.com. For media inquiries, Nic Johnson and Elio Ambrosio from Russo Partners can be contacted at nic.johnson@russopartnersllc.com and elio.ambrosio@russopartnersllc.com.

Frequently Asked Questions

What is Gain Therapeutics' primary focus?

Gain Therapeutics is dedicated to discovering and developing allosteric therapies aimed at treating challenging diseases, such as Parkinson’s.

Who will represent Gain Therapeutics at the conference?

The company will be represented by Gene Mack, the Interim CEO, and Dr. Jonas Hannestad, the Chief Medical Officer.

How can someone connect with Gain Therapeutics during the conference?

Individuals interested in connecting with Gain can reach out via email to arrange meetings.

What is the significance of the Magellan™ platform?

The Magellan™ platform enables Gain to identify novel allosteric binding sites, enhancing their capabilities in drug discovery.

What stage is GT-02287 currently in?

GT-02287 is currently in a Phase 1 clinical trial aimed at treating Parkinson’s disease.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 97

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 103

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 67

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 10

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 72

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 71

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 152

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Rush to ExoraPad: The Rise of $EXP Tokens Explained

Updated Category News Views 219

Investors Flock to ExoraPad as the $EXP Token Presale Surges As the digital currency landscape evolves, many investors are seeking the next big opportunity. ExoraPad has emerged as a focal point in this space, particularly for those involved with XRP. The ongoing presale for the $EXP token has garnered immense attention, attracting numerous investors eager to secure their...

Continue Reading
Key Insights on DFDS A/S Share Transactions Involving Managers

Updated Category News Views 251

Recent Share Transactions by DFDS A/S Leadership On February 25, a significant transaction was recorded involving Claus V. Hemmingsen, the Chair of the Board of Directors for DFDS A/S, who purchased 5,000 shares of the company. This action showcases the confidence of the company’s leadership in its growth trajectory and operational strategy. Regulatory Obligations Under...

Continue Reading
First Guaranty Bancshares Reaches New Stock Milestone

Updated Category News Views 253

First Guaranty Bancshares Achieves New Milestone First Guaranty Bancshares Inc (NASDAQ: FGBI) has recently achieved a notable milestone, with its stock hitting a new 52-week high of $13.38. This impressive leap highlights a phase of robust growth for the company, reflected in the rising stock price that has been buoyed by favorable market sentiments. Over the past year,...

Continue Reading
Pho Hoa & Jazen Tea Expands Southeast with New Location

Updated Category News Views 314

Pho Hoa & Jazen Tea Expands into the Southeast Pho Hoa & Jazen Tea is excited to announce the grand opening of a new restaurant in Marietta, marking an important milestone in the brand's expansion strategy. With over 40 years dedicated to perfecting pho noodle soup, the company is eager to bring its incredible Vietnamese culinary experience to new customers. Exciting New...

Continue Reading
IDT Corporation's Commitment to Shareholders with New Dividend

Updated Category News Views 74

IDT Corporation Announces Quarterly Dividend for Shareholders IDT Corporation (NYSE: IDT), a key player in communications and payment services, has recently made waves by declaring a quarterly cash dividend of $0.05 per share. This news was shared through a regulatory filing, illustrating the company's ongoing commitment to providing value to its shareholders. Details on...

Continue Reading